Q: What are your views on GVP?
Thanks.
Grant
Thanks.
Grant
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Can IWO be held inside a TFSA since it consists of american stocks. Is there a 15% claw back on the dividend. Would it really be considered a growth name since it consists of many companies. Thank You for the great service.
Q: Just curious if you had any insights to AcuityAds, I see there raising some money but as I write this no detail in regards to pricing and size of the offer have been given. Thanks for your input,
Q: Is Carmanah breaking out?
Q: Hi, you talked about Fly-v on BNN today but I was unable to catch the commentary. Do you like the company given it has no debt and is in a growing business?
Q: Howdy,
CDV looks like a quality small cap in an industry with a high barrier to entry. But top line growth has been flat as a pancake for the past seven years. What corporate developments lead you to think that revenue and earnings will accelerate materially at this point in the companies history?
5i = best service for retail investors in Canada.
Thanks.
CDV looks like a quality small cap in an industry with a high barrier to entry. But top line growth has been flat as a pancake for the past seven years. What corporate developments lead you to think that revenue and earnings will accelerate materially at this point in the companies history?
5i = best service for retail investors in Canada.
Thanks.
Q: Hi, today on Marketcall Mark mentioned to Peter another new company related to the management team of PHM and Convalo, did I get the name right and is it trading already? Greetings, Peter.
Q: Hi Team - could you provide a general comment/opinion on the company and what you think of its recent NR with respect to the Google partnership? Thanks
Q: Many cannabis startups are stagnant or declining, but CANN seems to be finding its feet. Is this just noise, or is CANN's pick-and-shovel focus getting traction in the market?
Q: hi folks:
repeatedly you have stated that kelso has a good balance sheet, good mgmt, and is in a good industry niche
AND always commented it to be 'very expensive'
assuming the above I ask....
given that it is directly related to the O/G sector yet given at $4.60 it is down +/- 35% at what point does it become reasonably priced (based on fundamentals), and at what point would it move to 'you'd be a dolt not to buy some'
thanks
repeatedly you have stated that kelso has a good balance sheet, good mgmt, and is in a good industry niche
AND always commented it to be 'very expensive'
assuming the above I ask....
given that it is directly related to the O/G sector yet given at $4.60 it is down +/- 35% at what point does it become reasonably priced (based on fundamentals), and at what point would it move to 'you'd be a dolt not to buy some'
thanks
Q: Hi Peter, Ryan & Team;
I am having nightmares about LSI. Is there any indication of when the company will come out with the year end financials?
Shareholders appear to be jumping ship.
FYI: Teenburgers at A&W for $3.00 (+ taxes). Thank you.
I am having nightmares about LSI. Is there any indication of when the company will come out with the year end financials?
Shareholders appear to be jumping ship.
FYI: Teenburgers at A&W for $3.00 (+ taxes). Thank you.
Q: Good afternoon 5I team,
I would like to have your opinion on DuSolo, would you consider this a buy at this time?
Thank you for your help, David K.
I would like to have your opinion on DuSolo, would you consider this a buy at this time?
Thank you for your help, David K.
Q: Peter, could you comment on Mandalay's first quarter results and the shareholder rights plan just announced. Was the recent 10 cent drop to 82 cents related to the "in-the-works" rights plan ?? Are you still positive on this stock going forward??
Q: Hi Peter! I have collected a few names in my portfolio that have shrunk to little value and am wondering if you think I should hold on to these names or just exit the positions and move on. I'm not losing much by holding on to them but am unclear on whether there is much upside with any of these names? Ian
Q: Caldwell Partners release fiscal Q2 last night. From revenue multiple the Company appears insanely cheap given that revenues are growing over 20%. What is your view on Caldwell as a small cap stock investment at current trading levels.
Q: Spectra has gained some momentum of recent with new products and "design ins". with the warrants out of the way and stronger capital position what do you think about SEV at this level?
Thank you
Thank you
Q: Hi Team,
Could you advise if you have an updated opinion on Neptune? Seems to me that the risk reward profile is becoming more favourable in light of their ore business stabilizing and potential for Acasti etc. would appreciate your thoughts.
Thank you
Could you advise if you have an updated opinion on Neptune? Seems to me that the risk reward profile is becoming more favourable in light of their ore business stabilizing and potential for Acasti etc. would appreciate your thoughts.
Thank you
Q: Please comment on the results announced today. Also, was ESP or SVC considered as candidates for your growth portfolio. What would be the one reason they were not selected.
Q: I'm thinking of selling ESP as it appears to be over valued. What is your opinion on its valuation? Thank you for your input.
Q: Hey 5i team,
The following is an email I received re ASG from Josh Sandberg, Founder, OrthoSpinenews. I thought it would be interesting for our family to read, but only if you feel it is appropriate to post it.
... Thank you for your thoughtful question. I think that ASG has a tough road ahead of them. There are many issues that have to be navigated before I believe the market will respond positively to the stock. I am not a stock advisor so please don’t take this as advice of whether or not you should hold or sell, however, I know the market of spine extremely well and there are many reasons why I wouldn’t invest my money in ASG. The product offering is limited which makes it difficult to get enough attention from independent distributors. They have had significant turnover in the executive staff (primarily in the VP of Sales role). I don’t know why that is but having a few executives come and go within 6 months of hire is a concern. Lastly, the use of marketing funds is a little bit of a head scratcher and they have become kind of a punchline of what not to do (regarding high burn). It seems that they wanted to blitz the market and try to sell quickly, which I just don’t see happening in the short term because there’s not enough value for a strategic in the foreseeable future.
The following is an email I received re ASG from Josh Sandberg, Founder, OrthoSpinenews. I thought it would be interesting for our family to read, but only if you feel it is appropriate to post it.
... Thank you for your thoughtful question. I think that ASG has a tough road ahead of them. There are many issues that have to be navigated before I believe the market will respond positively to the stock. I am not a stock advisor so please don’t take this as advice of whether or not you should hold or sell, however, I know the market of spine extremely well and there are many reasons why I wouldn’t invest my money in ASG. The product offering is limited which makes it difficult to get enough attention from independent distributors. They have had significant turnover in the executive staff (primarily in the VP of Sales role). I don’t know why that is but having a few executives come and go within 6 months of hire is a concern. Lastly, the use of marketing funds is a little bit of a head scratcher and they have become kind of a punchline of what not to do (regarding high burn). It seems that they wanted to blitz the market and try to sell quickly, which I just don’t see happening in the short term because there’s not enough value for a strategic in the foreseeable future.